ArticleClinical kidney journal2026
Continuation of sodium-glucose co-transporter 2 inhibitors in advanced chronic kidney disease: a retrospective study with inverse probability of treatment weighting analysis.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) slow the progression of chronic kidney disease (CKD). However, the evidence to support the continuation of SGLT2i when estimated glomerular filtration rate (eGFR) falls below 20 mL/min/1.73 m Methods: Between 2015 and 2021, we identified 1011 CKD patients who received SGLT2i for at least 3 months and had eGFR that had progressed to ≤20 mL/min/1.73 m Results: The median follow-up was 14.3 months (interquartile range 8.7-21.8 months). The IPTW-adjusted 2-year dialysis-free survival rates of the Discontinuation and Continuation groups were 41.7% and 58.9%, respectively (weighted log rank test, Conclusion: In CKD patients who received SGLT2i therapy, continuation of the SGLT2i therapy after the eGFR fell below 20 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.